Synovus Financial Corp raised its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 59,751 shares of the medical research company’s stock after purchasing an additional 2,627 shares during the period. Synovus Financial Corp’s holdings in Amgen were worth $11,636,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Ruggie Capital Group raised its position in shares of Amgen by 297.1% during the 4th quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after buying an additional 101 shares in the last quarter. Arlington Partners LLC raised its position in shares of Amgen by 86.7% during the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after buying an additional 65 shares in the last quarter. Massey Quick Simon & CO. LLC raised its position in shares of Amgen by 710.5% during the 4th quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after buying an additional 135 shares in the last quarter. Essex Investment Management Co. LLC purchased a new stake in shares of Amgen during the 4th quarter valued at about $39,000. Finally, Contravisory Investment Management Inc. purchased a new stake in shares of Amgen during the 4th quarter valued at about $50,000. 78.13% of the stock is owned by institutional investors and hedge funds.
Amgen stock opened at $191.24 on Friday. The company has a debt-to-equity ratio of 2.36, a quick ratio of 2.57 and a current ratio of 2.79. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $210.19. The stock has a market capitalization of $116.84 billion, a P/E ratio of 13.28, a PEG ratio of 2.25 and a beta of 1.21.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.26 by $0.16. Amgen had a net margin of 35.35% and a return on equity of 66.74%. The company had revenue of $6.23 billion for the quarter, compared to analyst estimates of $5.88 billion. During the same period in the prior year, the company posted $2.89 EPS. Sell-side analysts expect that Amgen, Inc. will post 13.97 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 40.28%.
In related news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total value of $377,760.00. Following the sale, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.
Several brokerages have recently issued reports on AMGN. BMO Capital Markets began coverage on shares of Amgen in a research report on Thursday. They set an “outperform” rating and a $228.00 target price on the stock. Mizuho restated a “buy” rating and set a $211.00 target price on shares of Amgen in a research report on Tuesday, February 26th. Cowen restated a “buy” rating and set a $234.00 target price on shares of Amgen in a research report on Tuesday, February 26th. BidaskClub cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Finally, Royal Bank of Canada restated a “neutral” rating on shares of Amgen in a research report on Friday, February 1st. Twelve investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $209.79.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.